Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and
may be a harbinger of dementia. In view of its importance, the Movement Disorder Society …

Cognitive abnormalities are common in Parkinson's disease, with important social and
economic implications. Factors influencing their evolution remain unclear but are crucial to the …

Background Prognosis in Parkinson's disease (PD) remains poorly understood due to a lack
of unbiased data on the natural history of treated PD. The CamPaIGN study has been the …

Mutations in leucine-rich repeat kinase 2 (LRRK2) cause inherited Parkinson disease (PD),
and common variants around LRRK2 are a risk factor for sporadic PD. Using protein–protein …

Soluble α-synuclein aggregates varying in size, structure, and morphology have been closely
linked to neuronal death in Parkinson’s disease. However, the heterogeneity of different co…

Objective Parkinson's disease (PD) is a neurodegenerative condition that typically presents
as a movement disorder but is known to be associated with variable degrees of cognitive …

Carriers of mutations in the glucocerebrosidase gene (GBA) are at increased risk of developing
Parkinson’s disease. The frequency of GBA mutations in unselected Parkinson’s disease …

Objective We hypothesized that specific mutations in the β‐glucocerebrosidase gene (GBA)
causing neuropathic Gaucher's disease (GD) in homozygotes lead to aggressive cognitive …

Background Our understanding of the natural history of idiopathic Parkinson's disease (PD)
remains limited. In the era of potential disease modifying therapies, there is an urgent need …

Background The immune system is a promising therapeutic target for disease modification in
Parkinson's disease (PD), but appropriate immune‐related biomarkers must be identified to …